Patrick Forde, MBBCh offers an overview of current standard-of-care treatments as well as emerging immunotherapy options for treating early-stage, resectable non-small cell lung cancer.
CNS Activity of Third-Generation ALK TKIs Influence Approach in NSCLC
June 21st 2024During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed with participants how they select treatment for a patient with ALK+ non–small cell lung cancer and brain metastases in the first article of a 2-part series.
Read More